Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Clemons

Showing results (261-270 of 267) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 267 results.
Clinical Breast Cancer|October 11, 2015
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast CancerMichael B Sawyer, Edith Pituskin, Sambasivarao Damaraju, et al.
NPJ Breast Cancer|November 23, 2019
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancerBen P Haynes, Ophira Ginsburg, Qiong Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2Mario Campone, Seock-Ah Im, Hiroji Iwata, et al.
The Lancet. Oncology|June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialJosé Baselga, Seock-Ah Im, Hiroji Iwata, et al.
Breast Cancer Research and Treatment|September 15, 2021
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancerBen P Haynes, Gene Schuster, Richard Buus, et al.
Journal of Medical Internet Research|April 14, 2026
Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation StudyLisa Pilgram, Kai Yang, Ana-Alicia Beltran-Bless, et al.
Journal of the National Cancer Institute|November 7, 2019
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307Julie R Gralow, William E Barlow, Alexander H G Paterson, et al.
Pageof 27

Showing results (261-270 of 267) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 267 results.
Clinical Breast Cancer|October 11, 2015
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast CancerMichael B Sawyer, Edith Pituskin, Sambasivarao Damaraju, et al.
NPJ Breast Cancer|November 23, 2019
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancerBen P Haynes, Ophira Ginsburg, Qiong Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2Mario Campone, Seock-Ah Im, Hiroji Iwata, et al.
The Lancet. Oncology|June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialJosé Baselga, Seock-Ah Im, Hiroji Iwata, et al.
Breast Cancer Research and Treatment|September 15, 2021
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancerBen P Haynes, Gene Schuster, Richard Buus, et al.
Journal of Medical Internet Research|April 14, 2026
Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation StudyLisa Pilgram, Kai Yang, Ana-Alicia Beltran-Bless, et al.
Journal of the National Cancer Institute|November 7, 2019
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307Julie R Gralow, William E Barlow, Alexander H G Paterson, et al.
Pageof 27